NCT04883697 is a clinical trial of vitrectomy with ILM peeling and ILM flap technique in Macular Holes, sponsored by Vienna Institute for Research in Ocular Surgery.

Who is sponsoring NCT04883697?

NCT04883697 is sponsored by Vienna Institute for Research in Ocular Surgery.

What drugs are being tested in NCT04883697?

Interventions in NCT04883697: vitrectomy with ILM peeling and ILM flap technique.

What condition does NCT04883697 study?

NCT04883697 studies Macular Holes.

Is NCT04883697 still recruiting?

NCT04883697 is currently completed. Last updated 12 May 2021.

Last reviewed 2021-05-12 · How we verify

NCT04883697

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retrospective Evaluation of Risk Factors for Lower Outcomes After Vitrectomy With ILM Flap Technique

Completed Last updated 12 May 2021

What this trial tests

trial testing vitrectomy with ILM peeling and ILM flap technique in Macular Holes in 71 participants. Completed in 1 May 2021.

Timeline

1 January 2021

Primary endpoint
1 May 2021

1 May 2021

Quick facts

Lead sponsor	Vienna Institute for Research in Ocular Surgery
Status	Completed
Study type	OBSERVATIONAL
Enrollment	71
Start date	1 January 2021
Primary completion	1 May 2021
Estimated completion	1 May 2021
Sites	1 location across Austria

Drugs / interventions tested

vitrectomy with ILM peeling and ILM flap technique

Conditions studied

Macular Holes — all drugs for Macular Holes →

Sponsor

Vienna Institute for Research in Ocular Surgery

Who can join

Adults 18 to 105, any sex, with Macular Holes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective review of medical charts of patients having undergone vitrectomy with ILM Peeling and ILM flap technique for macular hole repair.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Macular Holes

Currently open trials in the same condition.

NCT06211907 — Small Macular Holes Treated With Air · NA · recruiting
NCT06000111 — Duration of Face Down Positioning for Full-Thickness Macular Hole Repair · NA · recruiting
NCT04904679 — The Use of Amniotic Membrane or Internal Limiting Membrane for Large or Refractory Macular Holes: A Prospective Study · NA · active not recruiting
NCT03713268 — Intraoperative OCT Guidance of Intraocular Surgery II · recruiting

Other Vienna Institute for Research in Ocular Surgery trials

Trials by the same sponsor.

NCT07262021 — Visual Function of Enhanced Monofocal Intraocular Lenses · NA · not yet recruiting
NCT06914817 — Brillouin Microscopy Used to Evaluate Corneal Mechanical Properties · NA · not yet recruiting
NCT07297849 — Eyelid Closure in Keratometry · NA · recruiting
NCT07390253 — Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration · active not recruiting
NCT06607848 — Comparison of Two Non- Diffractive Extended Depth of Focus Intraocular Lenses · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04883697 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vienna Institute for Research in Ocular Surgery
Last refreshed: 12 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04883697.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing